GlassScriptPhysician profile
Amanda Sewell
NPI 1205500386
$11,061.80
in general payments reported to CMS, 2019-2025
34 companies · $3,128 in 2025
The $3,128 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $772 · 2022: $1,890 · 2023: $2,086 · 2024: $3,186 · 2025: $3,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,372 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,372.49 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,606.54 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,487.52 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $1,264.57 | 2021-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $902.95 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $637.65 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $409.73 | 2021-2025 | Gattex, Entyvio |
| Madrigal Pharmaceuticals | $398.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $302.41 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $290.46 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $270.82 | 2021-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $259.44 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $256.54 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $251.97 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $248.48 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $195.36 | 2023-2024 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $180.10 | 2023-2025 | Sucraid |
| Braintree Laboratories, INC. | $159.38 | 2022-2025 | Suflave, Sutab |
| Celgene Corporation | $121.27 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $117.82 | 2021-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $113.47 | 2021 | |
| Pfizer INC. | $111.96 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $102.94 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $80.59 | 2023-2024 | Idacio |
| Redhill Biopharma INC. | $65.91 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Daiichi Sankyo INC. | $41.05 | 2021-2022 | |
| Procept Biorobotics Corporation | $35.91 | 2024 | Aquabeam System |
| Evoke Pharma, INC. | $30.68 | 2021-2025 | |
| Amgen INC. | $19.55 | 2022 | |
| Pharmacosmos Therapeutics INC. | $18.61 | 2022 | |
| Orphalan INC | $18.27 | 2024 | Cuvrior |
| E.R. Squibb & Sons, L.L.C. | $18.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.71 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $13.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sewell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.